FRANKLIN LAKES, N.J.,
Oct. 18, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, issued the following statement
regarding today's clearance by the European Commission for BD to
acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft
tissue core needle biopsy product line:
"We continue to make good progress on the Bard acquisition and
the conditional clearance from the European Commission is a
positive step forward," said Vincent A.
Forlenza, chairman and CEO of BD. "As expected, we have
committed to divesting certain assets associated with our soft
tissue core needle biopsy product line, which we acquired with
CareFusion, to satisfy the conditions to closing requested by the
European Commission. We continue to expect that the BD and Bard
transaction will close in the fourth calendar quarter of 2017,
subject to customary closing conditions and additional regulatory
approvals, including the U.S. Federal Trade Commission and other
regulatory bodies."
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" within
the meaning of the federal securities laws, including Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements are
based on the current expectations of BD management and are not
predictions of actual performance. These statements are subject to
a number of risks and uncertainties regarding BD and Bard's
respective businesses and the proposed acquisition, and actual
results may differ materially. These risks and uncertainties
include, but are not limited to, factors discussed in BD's filings
with the Securities and Exchange Commission. The forward-looking
statements in this document speak only as of date of this document.
BD undertakes no obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof, except as required by applicable laws or regulations.
Contacts:
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
|
BD Public
Relations
|
BD Investor
Relations
|
|
858.617.2361
|
201.847.5378
|
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
|
View original
content:http://www.prnewswire.com/news-releases/bd-statement-on-european-commission-conditional-clearance-of-bard-acquisition-300538889.html
SOURCE BD (Becton, Dickinson and Company)